![BioCentury This Week artwork](https://is5-ssl.mzstatic.com/image/thumb/Podcasts123/v4/fb/22/95/fb22950f-4f1e-4c27-1678-e9d26780c410/mza_11443144383013806162.jpg/100x100bb.jpg)
Ep. 134 - Preclinical Deal Making, Bluebird's Approval & Epigenome Editing
BioCentury This Week
English - August 22, 2022 21:00 - 19 minutes - 13.7 MB - ★★★★★ - 11 ratingsScience biotech biopharma pharmaceutical research investment dealmaking Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: Ep. 133 - Financing Thaw? Plus: Protein Design & China Audits
Next Episode: Ep 135 Pt. 1 - Back to School 2022 Overview
Despite public market investors shying away from preclinical companies amid biotech’s bear market, large biopharmas have ramped up their deal making for early-stage assets and technologies and are willing to pay for access to new modalities, says BioCentury’s Stephen Hansen on the latest BioCentury This Week podcast. Hansen and colleagues also discuss the implications of FDA’s approval of gene therapy Zynteglo from bluebird bio Inc., and the latest advances and leaders in the field of epigenome editing.